Avenue EBITDA from 2010 to 2025
| ATXI Stock | USD 0.38 0.04 9.52% |
Check Avenue Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avenue Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Avenue financial statements analysis is a perfect complement when working with Avenue Therapeutics Valuation or Volatility modules.
Avenue |
About Avenue Therapeutics Financial Statements
Investors use fundamental indicators, such as Avenue Therapeutics' EBITDA, to determine how well the company is positioned to perform in the future. Although Avenue Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acuteintensive care hospital setting. The company was incorporated in 2015 and is based in New York, New York. Avenue Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Avenue Pink Sheet
Avenue Therapeutics financial ratios help investors to determine whether Avenue Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Avenue with respect to the benefits of owning Avenue Therapeutics security.